Download PDF
Semin Liver Dis 2020; 40(03): 213-224
DOI: 10.1055/s-0040-1708812
Review Article

Hepatitis C Virus Treatment in Children: A Challenge for Hepatitis C Virus Elimination

Manal H. El-Sayed
1   Department of Pediatrics, Faculty of Medicine, Clinical Research Center, Ain Shams University, Cairo, Egypt
,
Giuseppe Indolfi
2   Pediatric and Liver Unit, Meyer Children's University Hospital and Department NEUROFARBA, University of Florence, Florence, Italy
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Hepatitis C is a global public health threat. The introduction of direct-acting antivirals (DAAs) brings the prospect of curing the 71 million people living with the disease, dramatically changing the landscape of hepatitis C. The World Health Organization developed a roadmap for the elimination and cure of hepatitis C by 2030 with a clear goal with measurable targets. However, there is a lack of a well-defined strategy to tackle the hepatitis C virus (HCV) problem in children and adolescents vis-à-vis the adult population. Hepatitis C in children and adolescents can be addressed as part of a national policy for elimination in the whole population, namely macroelimination, or could be fragmented into a microelimination approach targeting the high-risk population groups. Children born to HCV-infected mothers, adolescents who are injecting drugs, migrants, and those suffering from inherited blood diseases are important target populations. After the U.S. Food and Drug Administration approval for the use of DAAs in children aged 3 years and above, evidence from clinical trials and real-world experience was accumulated using brand and generic medicines, with sustained virological response rates exceeding 95%. The evidence created should guide policies on the management of hepatitis C in children and adolescents. There are many challenges in managing HCV in this left-behind marginalized population. The lack of awareness and epidemiological data, consent age, prohibitive prices of medicines, and absence of policies on access to diagnostics, treatment, and linkage to care are among the many barriers to service delivery that should be addressed to achieve the elimination goal by 2030.

Keywords

elimination of HCV - chronic hepatitis C - children and adolescents - direct-acting antivirals


Publication History

Article published online:
11 June 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Cooke GS, Andrieux-Meyer I, Applegate TL. , et al; Lancet Gastroenterology & Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol 2019; 4 (02) 135-184
    CrossrefPubMedGoogle Scholar
  • 2 World Health Organization. Global Hepatitis Report, 2017. Geneva: World Health Organization; 2017
    Google Scholar
  • 3 Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2 (03) 161-176
    CrossrefPubMedGoogle Scholar
  • 4 World Health Organization. Global health sector strategy on viral hepatitis, 2016–2021: towards ending viral hepatitis. 2016 . Available at: http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf . Accessed October 16, 2019
    Google Scholar
  • 5 Schmelzer J, Dugan E, Blach S. , et al. Global prevalence of hepatitis C virus infection infection in children in 2018: a modelling study. Gastroenterol Hepatol 2020; (e-pub ahead of print) DOI: 10.1016/S2468-1253(19)30385-1.
    CrossrefPubMedGoogle Scholar
  • 6 Razavi H, El-Sayed M. Updated Global Estimate of HCV Infection in the Pediatric Population. Available at: http://cdafound.org/content/Downloads/Pediatric%20Prevalence%20161201.pdf . Accessed October 18, 2019
    Google Scholar
  • 7 Bortolotti F, Verucchi G, Cammà C. , et al; Italian Observatory for HCV Infection and Hepatitis C in Children. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134 (07) 1900-1907
    CrossrefPubMedGoogle Scholar
  • 8 European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005; 41 (01) 45-51
    CrossrefPubMedGoogle Scholar
  • 9 Jara P, Resti M, Hierro L. , et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003; 36 (03) 275-280
    CrossrefPubMedGoogle Scholar
  • 10 Iorio R, Giannattasio A, Sepe A, Terracciano LM, Vecchione R, Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis 2005; 41 (10) 1431-1437
    CrossrefPubMedGoogle Scholar
  • 11 Indolfi G, Guido M, Azzari C, Resti M. Histopathology of hepatitis C in children, a systematic review: implications for treatment. Expert Rev Anti Infect Ther 2015; 13 (10) 1225-1235
    CrossrefPubMedGoogle Scholar
  • 12 Goodman ZD, Makhlouf HR, Liu L. , et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008; 47 (03) 836-843
    CrossrefPubMedGoogle Scholar
  • 13 Guido M, Bortolotti F, Leandro G. , et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time?. Am J Gastroenterol 2003; 98 (03) 660-663
    CrossrefPubMedGoogle Scholar
  • 14 Castellino S, Lensing S, Riely C. , et al. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort. Blood 2004; 103 (07) 2460-2466
    CrossrefPubMedGoogle Scholar
  • 15 González-Peralta RP, Langham Jr MR, Andres JM. , et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009; 48 (05) 630-635
    CrossrefPubMedGoogle Scholar
  • 16 El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol 2013; 19 (44) 7880-7888
    CrossrefPubMedGoogle Scholar
  • 17 Rodrigue JR, Balistreri W, Haber B. , et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009; 48 (03) 341-347
    CrossrefPubMedGoogle Scholar
  • 18 Indolfi G, Easterbrook P, Dusheiko G. , et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol 2019; 4 (06) 477-487
    CrossrefPubMedGoogle Scholar
  • 19 The World Bank. Population ages 0-14 (% of total population). Available at: https://data.worldbank.org/indicator/SP.POP.0014.TO.ZS . Accessed October 2019
    Google Scholar
  • 20 UNICEF. Adolescent demographics. Available at: https://data.unicef.org/topic/adolescents/demographics/#status . Accessed October 2019
    Google Scholar
  • 21 Sheehan P, Sweeny K, Rasmussen B. , et al. Building the foundations for sustainable development: a case for global investment in the capabilities of adolescents. Lancet 2017; 390 (10104): 1792-1806
    CrossrefPubMedGoogle Scholar
  • 22 Chappell CA, Hillier SL, Crowe D, Meyn LA, Bogen DL, Krans EE. Hepatitis C virus screening among children exposed during pregnancy. Pediatrics 2018; 141 (06) e20173273
    CrossrefPubMedGoogle Scholar
  • 23 Rosen HR. “Hep C, where art thou”: what are the remaining (fundable) questions in hepatitis C virus research?. Hepatology 2017; 65 (01) 341-349
    CrossrefPubMedGoogle Scholar
  • 24 Lazarus JV, Wiktor S, Colombo M, Thursz M. EASL International Liver Foundation. Micro-elimination - a path to global elimination of hepatitis C. J Hepatol 2017; 67 (04) 665-666
    CrossrefPubMedGoogle Scholar
  • 25 Sokal E, Nannini P. Hepatitis C virus in children: the global picture. Arch Dis Child 2017; 102 (07) 668-671
    CrossrefPubMedGoogle Scholar
  • 26 Chemaitelly H, Mahmud S, Kouyoumjian SP, Al-Kanaani Z, Hermez JG, Abu-Raddad LJ. Who to test for hepatitis C virus in the Middle East and North Africa?: pooled analyses of 2,500 prevalence measures, including 49 million tests. Hepatol Commun 2019; 3 (03) 325-339
    CrossrefPubMedGoogle Scholar
  • 27 Waddington C, Sambo C. Financing health care for adolescents: a necessary part of universal health coverage. Bull World Health Organ 2015; 93 (01) 57-59
    CrossrefPubMedGoogle Scholar
  • 28 Suryaprasad AG, White JZ, Xu F. , et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 2014; 59 (10) 1411-1419
    CrossrefPubMedGoogle Scholar
  • 29 Zibbell JE, Iqbal K, Patel RC. , et al; Centers for Disease Control and Prevention (CDC). Increases in hepatitis C virus infection related to injection drug use among persons aged £30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep 2015; 64 (17) 453-458
    PubMedGoogle Scholar
  • 30 Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 2014; 59 (06) 765-773
    CrossrefPubMedGoogle Scholar
  • 31 Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011; 60 (17) 537-541
    PubMedGoogle Scholar
  • 32 Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. Hepatol Commun 2017; 1 (02) 87-98
    CrossrefPubMedGoogle Scholar
  • 33 Modin L, Arshad A, Wilkes B. , et al. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol 2019; 70 (03) 371-378
    CrossrefPubMedGoogle Scholar
  • 34 Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol 2014; 11 (01) 28-35
    CrossrefPubMedGoogle Scholar
  • 35 Save the Children. Complete End of Childhood Index. The Complete Face of Exclusion. Available at: https://www.savethechildren.org/content/dam/global/reports/2018-end-of-childhood-report.pdf . Accessed October 2019
    Google Scholar
  • 36 UNICEF. Preparing for the Future of Children and Youth in Syria and the Region through Education: London One Year On. Available at: http://childrenofsyria.info/2017/04/04/preparing-for-the-future-of-children-and-youth-in-syria-and-the-region-through-education-london-one-year-on/ . Accessed October 2019
    Google Scholar
  • 37 Centers for Disease Control and Prevention. Viral Hepatitis Surveillance—United States, 2015. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2017
    Google Scholar
  • 38 Ly KN, Jiles RB, Teshale EH, Foster MA, Pesano RL, Holmberg SD. Hepatitis C virus infection among reproductive-aged women and children in the United States, 2006 to 2014. Ann Intern Med 2017; 166 (11) 775-782
    CrossrefPubMedGoogle Scholar
  • 39 Spera AM, Eldin TK, Tosone G, Orlando R. Antiviral therapy for hepatitis C: has anything changed for pregnant/lactating women?. World J Hepatol 2016; 8 (12) 557-565
    CrossrefPubMedGoogle Scholar
  • 40 AASLD/IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: https://www.hcvguidelines.org/sites/default/files/full%E2%80%90guidance%E2%80%90pdf/HCVGuidance_May_24_2018b.pdf . Accessed December 2019
    Google Scholar
  • 41 Yattoo NG. Treatment of chronic hepatitis C with ledipasvir/sofosbuvir combination during pregnancy. Presented at the 27th Annual Conference of APASL, March 14–18, 2018, New Delhi, India:
    Google Scholar
  • 42 Chappell CA, Krans EE, Bunge K. , et al. A phase I study of ledipasvir/sofosbuvir in pregnant women with hepatitis C virus. Presented at the Conference on Retroviruses and Opportunistic Infections, March 8–11, 2020, Boston, MA
    Google Scholar
  • 43 El-Sayed MH, Elakel W, Elsharkawy A. , et al. DAA therapy in women of child bearing age: accidental conception during therapy and pregnancy outcome. Presented at the International Liver Congress by the European Association for the Study of the Liver, April 10–14, 2019, Vienna, Austria
    Google Scholar
  • 44 Freriksen JJM, van Seyen M, Judd A. , et al. Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child. Aliment Pharmacol Ther 2019; 50 (07) 738-750
    CrossrefPubMedGoogle Scholar
  • 45 Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68 (32) 698-702
    CrossrefPubMedGoogle Scholar
  • 46 Lazarus JV, Safreed-Harmon K, Thursz MR. , et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis 2018; 38 (03) 181-192
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Greenaway C, Thu Ma A, Kloda LA. , et al. The seroprevalence of hepatitis C antibodies in immigrants and refugees from intermediate and high endemic countries: a systematic review and meta-analysis. PLoS One 2015; 10 (11) e0141715
    CrossrefPubMedGoogle Scholar
  • 48 UNICEF. Child Refugees and Migrants. Available at: https://www.unicefusa.org/mission/emergencies/child-refugees . Accessed October 14, 2019
    Google Scholar
  • 49 World Health Organization. Guidelines on Hepatitis B and C testing. Available at: https://apps.who.int/iris/bitstream/handle/10665/254621/9789241549981-eng.pdf?sequence=1 . Accessed December 2019
    Google Scholar
  • 50 Fernandez M, Manzanares S, Jacques C, Caylá J, Kunkel J, Foster G. Screening for chronic viral hepatitis in migrant populations–Report on Four HEPscreen Pilot Studies screening for chronic viral hepatitis in migrant populations. Available at: http://hepscreen.eu/wp-content/uploads/2014/12/HEPscreen_Final-WP6-report_Pilot-studies.pdf . Accessed December 2019
    Google Scholar
  • 51 Jafferbhoy H, Miller MH, McIntyre P, Dillon JF. The effectiveness of outreach testing for hepatitis C in an immigrant Pakistani population. Epidemiol Infect 2012; 140 (06) 1048-1053
    CrossrefPubMedGoogle Scholar
  • 52 Perumalswami PV, DeWolfe Miller F, Orabee H. , et al. Hepatitis C screening beyond CDC guidelines in an Egyptian immigrant community. Liver Int 2014; 34 (02) 253-258
    CrossrefPubMedGoogle Scholar
  • 53 Perumalswami PV, Factor SH, Kapelusznik L. , et al. Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol 2013; 58 (05) 890-897
    CrossrefPubMedGoogle Scholar
  • 54 Zuure FR, Bouman J, Martens M. , et al. Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. Liver Int 2013; 33 (05) 727-738
    CrossrefPubMedGoogle Scholar
  • 55 Hargreaves S, Seedat F, Car J. , et al. Screening for latent TB, HIV, and hepatitis B/C in new migrants in a high prevalence area of London, UK: a cross-sectional study. BMC Infect Dis 2014; 14: 657
    CrossrefPubMedGoogle Scholar
  • 56 Bottero J, Boyd A, Gozlan J. , et al. Simultaneous human immunodeficiency virus-hepatitis B-hepatitis C point-of-care tests improve outcomes in linkage-to-care: results of a randomized control trial in persons without healthcare coverage. Open Forum Infect Dis 2015; 2 (04) ofv162
    CrossrefPubMedGoogle Scholar
  • 57 Rumi MG, Di Marco V, Colombo M. Management of HCV-Related Liver Disease in Hemophilia and Thalassemia. Semin Liver Dis 2018; 38 (02) 112-120
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 World Health Organization. Global Status Report on Blood Safety and Availability. Available at: https://apps.who.int/iris/bitstream/handle/10665/254987/9789241565431-eng.pdf?sequence=1 . Accessed October 18, 2019
    Google Scholar
  • 59 Zhang M, Rosenberg PS, Brown DL. , et al; Second Multicenter Hemophilia Cohort Study. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood 2006; 107 (03) 892-897
    CrossrefPubMedGoogle Scholar
  • 60 Lai ME, Origa R, Danjou F. , et al. Natural history of hepatitis C in thalassemia major: a long-term prospective study. Eur J Haematol 2013; 90 (06) 501-507
    CrossrefPubMedGoogle Scholar
  • 61 Katsanos KHCA, Christodoulou DK, Tzambouras N, Zervou Eleftheria Bourandas KL, Tsianos EV. Epidemiological and clinical characteristics of HCV infection in transfusion dependent thalassemia. Ann Gastroenterol 2005; 18: 54-56
    PubMedGoogle Scholar
  • 62 Prati D, Zanella A, Farma E. , et al. A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta-thalassemia. Blood 1998; 92 (09) 3460-3464
    CrossrefPubMedGoogle Scholar
  • 63 Jang TY, Lin PC, Huang CI. , et al. Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. PLoS One 2017; 12 (06) e0178883
    CrossrefPubMedGoogle Scholar
  • 64 Ahmed Kiani R, Anwar M, Waheed U, Asad MJ, Abbasi S, Abbas Zaheer H. Epidemiology of transfusion transmitted infection among patients with β-thalassaemia major in Pakistan. J Blood Transfus 2016; 2016: 8135649
    CrossrefPubMedGoogle Scholar
  • 65 Jafroodi M, Davoudi-Kiakalayeh A, Mohtasham-Amiri Z, Pourfathollah AA, Haghbin A. Trend in prevalence of hepatitis C virus infection among β-thalassemia major patients: 10 years of experience in Iran. Int J Prev Med 2015; 6: 89
    CrossrefPubMedGoogle Scholar
  • 66 Al-Naamani K, Al-Zakwani I, Al-Sinani S, Wasim F, Daar S. Prevalence of hepatitis C among multi-transfused thalassaemic patients in Oman: single centre experience. Sultan Qaboos Univ Med J 2015; 15 (01) e46-e51
    PubMedGoogle Scholar
  • 67 Chakrabarty P, Rudra S, Hossain MA. Prevalence of HBV and HCV among the multi-transfused beta thalassemic major patients in a day care centre of blood transfusion department of Mymensingh Medical College Hospital. Mymensingh Med J 2014; 23 (02) 235-241
    PubMedGoogle Scholar
  • 68 Hussein E. Evaluation of infectious disease markers in multitransfused Egyptian children with thalassemia. Ann Clin Lab Sci 2014; 44 (01) 62-66
    PubMedGoogle Scholar
  • 69 Mansour AK, Aly RM, Abdelrazek SY. , et al. Prevalence of HBV and HCV infection among multi-transfused Egyptian thalassemic patients. Hematol Oncol Stem Cell Ther 2012; 5 (01) 54-59
    CrossrefPubMedGoogle Scholar
  • 70 Al-Sweedan SA, Jaradat S, Amer K, Hayajneh W, Haddad H. Seroprevalence and genotyping of hepatitis C virus in multiple transfused Jordanian patients with β-thalassemia major. Turk J Haematol 2011; 28 (01) 47-51
    CrossrefPubMedGoogle Scholar
  • 71 Walsh CE, Workowski K, Terrault NA. , et al. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. Haemophilia 2017; 23 (02) 198-206
    CrossrefPubMedGoogle Scholar
  • 72 Nagao A, Hanabusa H. Brief report: the impact of ledipasvir/ sofosbuvir on HIV-positive and HIV-negative Japanese hemo-philia patients with 1, 4, and mixed-genotype HCV. J Acquir Immune Defic Syndr 2017; 74 (04) 418-422
    CrossrefPubMedGoogle Scholar
  • 73 Stedman CAM, Hyland RH, Ding X, Pang PS, McHutchison JG, Gane EJ. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia 2016; 22 (02) 214-217
    CrossrefPubMedGoogle Scholar
  • 74 Lee HW, Yoo KY, Won JW, Kim HJ. Direct acting antiviral agents in Korean patients with chronic hepatitis C and hemophilia who are treatment-naïve or treatment-experienced. Gut Liver 2017; 11 (05) 721-727
    CrossrefPubMedGoogle Scholar
  • 75 Hézode C, Colombo M, Bourlière M. , et al; C-EDGE IBLD Study Investigators. Elbasvir/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III study. Hepatology 2017; 66 (03) 736-745
    CrossrefPubMedGoogle Scholar
  • 76 Sinakos E, Kountouras D, Koskinas J. , et al. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease. Br J Haematol 2017; 178 (01) 130-136
    CrossrefPubMedGoogle Scholar
  • 77 Mangia A, Sarli R, Gamberini R. , et al. Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. Aliment Pharmacol Ther 2017; 46 (04) 424-431
    CrossrefPubMedGoogle Scholar
  • 78 Origa R, Ponti ML, Filosa A. , et al; Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE). Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. Am J Hematol 2017; 92 (12) 1349-1355
    CrossrefPubMedGoogle Scholar
  • 79 Nagral A, Sawant S, Nagral N, Parikh P, Malde P, Merchant R. Generic direct acting antivirals in treatment of chronic hepatitis C infection in patients of thalassemia major. J Clin Exp Hepatol 2017; 7 (03) 172-178
    CrossrefPubMedGoogle Scholar
  • 80 European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017; 66 (01) 153-164
    CrossrefPubMedGoogle Scholar
  • 81 European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018; 69 (02) 461-511
    CrossrefPubMedGoogle Scholar
  • 82 Indolfi G, Hierro L, Dezsofi A. , et al. Treatment of chronic hepatitis C virus infection in children: a position paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 66 (03) 505-515
    CrossrefPubMedGoogle Scholar
  • 83 Murray KF, Balistreri WF, Bansal S. , et al. Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6-11. Hepatology 2018; 68 (06) 2158-2166
    CrossrefPubMedGoogle Scholar
  • 84 Schwarz KB, Rosenthal P, Murray KF. , et al. Ledipasvir-sofosbuvir for 12 weeks in children 3 to <6 years old with chronic hepatitis C. Hepatology 2020; 71 (02) 422-430
    CrossrefPubMedGoogle Scholar
  • 85 Balistreri WF, Murray KF, Rosenthal P. , et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017; 66 (02) 371-378
    CrossrefPubMedGoogle Scholar
  • 86 Garrison K, Mathias A, Kersey K. , et al. Pharmacokinetics of once daily sofosbuvir or ledipasvir/sofosbuvir in HCV-infected pediatrics aged 6 to <12 years old. Paper presented at the Liver Meeting, November 11–15, 2016, Boston, MA
    Google Scholar
  • 87 El-Khayat HR, Kamal EM, El-Sayed MH. , et al. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Aliment Pharmacol Ther 2018; 47 (06) 838-844
    CrossrefPubMedGoogle Scholar
  • 88 El-Karaksy H, Mogahed EA, Abdullatif H. , et al. Sustained viral response in genotype 4 chronic hepatitis C virus-infected children and adolescents treated with sofosbuvir/ledipasvir. J Pediatr Gastroenterol Nutr 2018; 67 (05) 626-630
    CrossrefPubMedGoogle Scholar
  • 89 Dhiman RK, Grover GS, Premkumar M. , et al. Direct-acting antiviral therapy is safe and effective in pediatric chronic hepatitis C: the public health perspective. J Pediatr Gastroenterol Nutr 2019; 68 (01) 74-80
    CrossrefPubMedGoogle Scholar
  • 90 El-Shabrawi MHF, Kamal NM, El-Khayat HR, Kamal EM, AbdElgawad MMAH, Yakoot M. A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12- year old children. Aliment Pharmacol Ther 2018; 47 (12) 1699-1704
    CrossrefPubMedGoogle Scholar
  • 91 El-Khayat H, Kamal EM, Yakoot M. , et al. Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients. Eur J Gastroenterol Hepatol 2019; 31 (08) 1004-1009
    CrossrefPubMedGoogle Scholar
  • 92 Serranti D, Dodi I, Nicastro E. , et al. Shortened 8-week course of sofosbuvir/ledipasvir therapy in adolescents with chronic hepatitis c infection. J Pediatr Gastroenterol Nutr 2019; 69 (05) 595-598
    CrossrefPubMedGoogle Scholar
  • 93 El-Sayed MH, Hassany M, El-Sayed Ebeid FS. , et al. Ledipasvir/sofosbuvir for 8 weeks cures genotype 4 chronic hepatitis C in non-cirrhotic children and adolescents. J Hepatol 2019; 70: e221
    CrossrefPubMedGoogle Scholar
  • 94 Wirth S, Rosenthal P, Gonzalez-Peralta RP. , et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 2017; 66 (04) 1102-1110
    CrossrefPubMedGoogle Scholar
  • 95 Rosenthal P, Schwarz KB, Gonzalez-Peralta RP. , et al. Sofosbuvir and ribavirin therapy for children aged 3 to <12 years with hepatitis C virus genotype 2 or 3 infection. Hepatology 2020; 71 (01) 31-43
    CrossrefPubMedGoogle Scholar
  • 96 Hashmi MA, Cheema HA. Effectiveness and safety of sofosbuvir in treatment-näive children with hepatitis C infection. J Coll Physicians Surg Pak 2017; 27 (07) 423-426
    PubMedGoogle Scholar
  • 97 Leung DH, Yao BB, Viani RM. , et al. ZIRCON: pharmacokinetics, safety, and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in adolescents with genotype 1 or 4 hepatitis C virus infection. Presented at the 52nd Annual Meeting of the European Association for the Study of the Liver, April 19–23, 2017, Amsterdam, the Netherlands
    Google Scholar
  • 98 Jonas MM, Squires RH, Rhee SM. , et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study. Hepatology 2020; 71 (02) 456-462
    CrossrefPubMedGoogle Scholar
  • 99 El-Sayed MH, Hassany M, Asem N. A pilot study for safety and efficacy of 12 weeks sofosbuvir plus daclatasvir with or without ribavirin in Egyptian adolescents with chronic hepatitis C virus Infection. J Hepatol 2017; 66 (01) S178
    CrossrefPubMedGoogle Scholar
  • 100 Yakoot M, El-Shabrawi MH, AbdElgawad MM. , et al. Dual sofosbuvir/daclatasvir therapy in adolescent patients with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2018; 67 (01) 86-89
    CrossrefPubMedGoogle Scholar
  • 101 Padhi S, Maharshi S, Gupta GK, Garg K, Nijhawan S. Efficacy and safety of direct acting antiviral therapy for chronic hepatitis C in thalassemic children. J Pediatr Hematol Oncol 2018; 40 (07) 511-514
    CrossrefPubMedGoogle Scholar
  • 102 Abdel Ghaffar TY, El Naghi S, Abdel Gawad M. , et al. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C genotype 4. J Viral Hepat 2019; 26 (02) 263-270
    CrossrefPubMedGoogle Scholar
  • 103 El-Shabrawi MH, Abdo AM, El-Khayat HR, Yakoot M. Shortened 8 weeks course of dual sofosbuvir/daclatasvir therapy in adolescent patients, with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2018; 66 (03) 425-427
    CrossrefPubMedGoogle Scholar
  • 104 Page K, Melia M, Rebecca T. Results of the First Prophylactic Hepatitis C Virus Vaccine Efficacy Trial. Presented at the IDWeek, October 2–6, 2019, Washington, DC
    Google Scholar
  • 105 Penazzato M, Watkins M, Morin S. , et al. Catalysing the development and introduction of paediatric drug formulations for children living with HIV: a new global collaborative framework for action. Lancet HIV 2018; 5 (05) e259-e264
    CrossrefPubMedGoogle Scholar